Paul D. Miller

ORCID: 0000-0003-3892-1553 · 3 papers in corpus
article 2023
10173 Long-Term Therapy of Elagolix + Add-Back Therapy in Women with Endometriosis-Associated Pain for 48 Months: Update on Bone Mineral Density
·doi:10.1016/j.jmig.2023.08.336
article 2023
Long-Term Safety of Elagolix With Add-Back in Women With Endometriosis-Associated Pain: 36-Month Results [ID: 1368036]
·doi:10.1097/01.aog.0000929852.03048.10

INTRODUCTION: Herein, we report updated safety results to 36 months from an ongoing phase 3, 48-month study evaluating the long-term safety of elagolix (ELA) with add-back (AB) for endometriosis-associated pain (EAP) (NCT03213457). METHODS:…

article 2022
Long-Term Safety of Elagolix With Hormonal Add-Back Therapy in Women With Endometriosis-Associated Pain: 24-Month Results [A86]
·doi:10.1097/01.aog.0000826672.69977.4c

INTRODUCTION: Elagolix is an oral GnRH antagonist approved for the treatment of moderate to severe endometriosis-associated pain (EAP) in the US, Canada, and Israel. Hormonal add-back therapy (1 mg estradiol/0.5 mg norethindrone acetate QD)…